导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.77% | 3488/4773 |
| 近一周 | -1.30% | 1987/5465 |
| 近一月 | 2.33% | 230/5421 |
| 近一季 | 3.16% | 490/5231 |
| 近半年 | 0.09% | 1370/4920 |
| 近一年 | -3.70% | 3115/4394 |
| 近两年 | 30.41% | 2261/2954 |
| 近三年 | 24.39% | 1327/2253 |
| 成立以来 | 136.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.81% 4322/4961 |
-3.76% 3475/5312 |
- - |
- - |
| 2025 | 10.34% 2821/4813 |
-1.58% 2698/3635 |
8.75% 315/4076 |
-1.19% 3949/4524 |
4.34% 539/4813 |
| 2024 | 29.67% 124/3463 |
3.47% 564/2808 |
1.41% 475/3014 |
21.08% 623/3129 |
2.06% 990/3463 |
| 2023 | -2.72% 603/2656 |
-0.64% 1813/2280 |
0.64% 293/2385 |
5.08% 100/2515 |
-7.43% 2146/2655 |
| 2022 | -12.41% 283/2207 |
-6.65% 222/1919 |
-0.68% 1646/2016 |
-11.02% 486/2113 |
6.16% 384/2208 |
| 2021 | -3.74% 926/1822 |
-1.13% 436/1255 |
- 1117/1330 |
-3.68% 653/1466 |
1.08% 1012/1822 |
| 2020 | 8.72% 854/1250 |
-14.54% 965/1022 |
5.09% 887/1060 |
12.89% 352/1152 |
- - |
| 2019 | 33.50% 431/1092 |
26.60% 388/748 |
1.62% 116/797 |
-2.26% 687/844 |
6.16% 645/912 |
| 2018 | -16.66% 112/834 |
- - |
- - |
- - |
-9.46% 145/691 |
| 2017 | 14.56% 254/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.93% 187/605 |
- - |
- - |
- - |
- - |
| 2015 | -11.89% 296/575 |
- - |
- - |
- - |
- - |
| 2014 | 85.89% 5/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 中信保诚中证800金融指数(LOF)A VS. 长安沪深300非周期A(740101) |